News | May 08, 2025
Suven Pharmaceuticals is now Cohance Lifesciences
The change of name has been carried on pursuant to the Scheme of Amalgamation
The change of name has been carried on pursuant to the Scheme of Amalgamation
Topiramate is indicated as a treatment of epilepsy and migraine
The company has posted net profit of Rs. 582.01 crores for the Financial Year ended March 31, 2025
This significant milestone enhances our global regulatory standing
Alembic Pharmaceuticals commissions new facility at Pithampur
This approval authorizes the company to export Ibuprofen to the Chinese markets
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
According to IQVIATM sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market3 achieved annual sales of approximately $421.7 million.
Mantri will replace V. S. Mani, Executive Director & Global Chief Financial Officer of the company as he has conveyed his decision to opt for early retirement
Subscribe To Our Newsletter & Stay Updated
